Delivery Order SPE2DR25D1017-SPE2DR26F9BFG
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,221.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,701.45 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price contract was issued on September 12, 2025, with an ultimate completion date of September 15, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $10,594.36 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under the company's larger...
- The Defense Logistics Agency awarded a $17,976.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of November 25, 2025. This non-set-aside competitive award was made to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,092.75 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by December 3, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,706.24 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of September 4, 2025. This firm fixed-price delivery order represents a non-competitive award, as no set-aside designation was applied. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,396.41 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector medication. This competitively awarded, non-set-aside contract has a firm fixed price structure with an ultimate completion date of October 27, 2025. AmerisourceBergen Drug Corp will perform the delivery from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $12,639.34 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This non-set-aside competitive award represents a child delivery order issued against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the vendor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of November...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,246.73 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on October 27, 2025, with an ultimate completion date of October 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9BFGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,170.93 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside contract was awarded on December 11, 2025, with an ultimate completion date of December 12, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $1 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains through competitive, non-set-aside procurements with the DLA. Repatha is a PCSK9 inhibitor used in cardiovascular disease management, reflecting the company's role in supplying specialized medications critical to military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 12/10/25 |